SCHEMBL316871

SCHEMBL316871

O=C(CBr)c1ccc(-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 1.00
PTPN1 P18031 5/20 1.00
SMN1; SMN2 Q16637 4/20 0.64
MAPT P10636 3/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
FFAR1 O14842 1/20 0.62
LMNA P02545 1/20 0.62
CYP1A2 P05177 1/20 0.62
RAB9A P51151 1/20 0.62
HIF1A Q16665 1/20 0.62
HPGD P15428 1/20 0.60
ERCC5 P28715 1/20 0.60
FEN1 P39748 1/20 0.60
HAO1 Q9UJM8 1/20 0.60
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 2/20 0.59
AGTR1 P30556 1/20 0.59
USP2 O75604 1/20 0.58
SRD5A2 P31213 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22004470 1.00 GSK3B (1.00) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL689331 0.91 GSK3B (0.83) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL8103554 0.86 GSK3B (0.77) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL19331717 0.86 GSK3B (1.00) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL7621 0.86 GSK3B (1.00) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL18849535 0.86 GSK3B (1.00) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL4324217 0.85 GSK3B (0.72) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
Hydrogen Sulfide SCHEMBL7496567 0.84 GSK3B (0.95) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
Methane SCHEMBL7161301 0.84 GSK3B (0.95) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1
Bromide SCHEMBL28774450 0.84 GSK3B (0.95) GSK3BPTPN1SMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 642 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119930622-A Antitumor matrine hydrazine thiazole derivative and preparation method and application thereof 南京林业大学 2025-05-06 CN claimed
CN-115368346-B 1, 4-benzodioxane-benzimidazole salt compound and synthesis method and application thereof 曲靖师范学院 2024-04-09 CN claimed
EP-3958980-B1 TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER ANADOLU UNIV (TR) 2023-11-15 EP claimed
CN-115368346-A 1, 4-benzodioxan-benzimidazole salt compound and synthesis method and application thereof 曲靖师范学院 2022-11-22 CN claimed
EP-3958980-A1 TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER Anadolu Universitesi (TR) 2022-03-02 EP claimed
WO-2021257020-A1 TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER ANADOLU ÜNİVERSİTESİ (TR) 2021-12-23 WO claimed
CN-110305048-A One kind preparing α-sulfuryl ketone compounds synthetic method by α, α-two bromo ketone one kettle way 温州大学 2019-10-08 CN claimed
EP-1140877-A1 HYPOLIPIDEMIC AND ANTIOXIDANT MORPHOLINE DERIVATIVES Elpen S.A. . (GR) 2001-10-10 EP claimed
WO-2000042030-A1 HYPOLIPIDEMIC AND ANTIOXIDANT MORPHOLINE DERIVATIVES ELPEN S.A. (GR) 2000-07-20 WO claimed
US-12595243-B2 Modulators of extracellular signal-regulated kinase GEN1E LIFESCIENCES INC. (US) 2026-04-07 US disclosed
CN-119930622-A Antitumor matrine hydrazine thiazole derivative and preparation method and application thereof 南京林业大学 2025-05-06 CN disclosed
CN-119930535-A 1,3, 4-Oxadiazole derivative containing biphenyl unit, and preparation method and application thereof 江苏海洋大学 2025-05-06 CN disclosed
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. 2025-05-01 US disclosed
WO-2025085745-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. (US) 2025-04-24 WO disclosed
US-3979440-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-09-07 US disclosed
US-3962218-A NOVEL PROSTANOIC ACID DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF SCHERING AKTIENGESELLSCHAFT (DT) 1976-06-08 US disclosed
US-3955982-A HYDROCARBONS, HAL EASTMAN KODAK COMPANY (US) 1976-05-11 US disclosed
US-3936447-A 7-Acylamino-desacetoxy-cephalosporanic acid esters and their production BAYER AKTIENGESELLSCHAFT (DT) 1976-02-03 US disclosed
US-3932338-A POLYOLEFINS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1976-01-13 US disclosed
US-3931407-A ANTIINFLAMMATORY, ANALGESIC AMERICAN HOECHST CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE MAP3K20, MAP3K6, CDC42BPG GSK3B 621/4885PTPN1 1149/4885SMN1; SMN2 4336/4885
US-12595243-B2 Modulators of extracellular signal-regulated kinase CDC42BPG, GRK3, ERBB2 GSK3B 727/4885PTPN1 206/4885SMN1; SMN2 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.